TABLE 5.
Intravenous | Oral | |||
---|---|---|---|---|
Dose (mg/kg) | 3 | 30 | 100 | 300 |
t1/2 (min) | 18.9 ± 1.25 | 14.9 ± 1.84 | 74.4 ± 11.1 | 117 ± 32.8a,b |
Cmax (ng/ml) | 335 ± 130 | 23,930 ± 825 | 4730 ± 563 | 14,494 ± 7806 |
tmax (min) | 10 | 5 | 23.6 ± 2.81 | 45 ± 4.59 |
AUC0–∞ (ng/ml/min) | 35,075 ± 4510 | 421,956 ± 21,095 | 336,452 ± 34,544 | 122,2925 ± 347,552 |
CL (ml/min/kg) | 98.6 ± 10.7 | 72.4 ± 3.29 | — | — |
CL/F (ml/min/kg) | — | — | 317 ± 32.2 | 375 ± 179 |
V (l/kg) | 2.66 ± 0.296 | 1.507 ± 0.135 | — | — |
V/F (l/kg) | — | — | 32.2 ± 3.33 | 52.1 ± 13.8 |
F (%) | — | — | 29.0 | 35.0 |
Dashes represent pharmacokinetic parameters not applicable to the defined treatment condition. aP < 0.05 from intravenous low dose.
bP < 0.05 from intravenous high dose.